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Objectives: Several studies have documented the potent in vitro activity of caspofungin against Candida
spp. This is of special concern for Candida glabrata infections that are often resistant to many azole
antifungal agents and, consequently, difficult to treat. The aim of the present study was to expand the
data on the in vitro activity of caspofungin against azole-resistant isolates of C. glabrata.
Methods: A total of 50 clinical isolates of C. glabrata were tested for susceptibility to caspofungin. The
isolates were cross-resistant to multiple azoles, including fluconazole, itraconazole, ketoconazole and
voriconazole. Expression of the resistance-related CgCDR1 and CgCDR2 genes was evaluated by
quantitativeRT–PCR analysis. TheMICs of caspofunginwere determined by using theNational Committee
for Clinical Laboratory Standards M27-A2 reference method.
Results: C. glabrata isolates exhibited increased expression of the CDR efflux pump(s), and this was in
accordance with their high-level azole resistance. In contrast, all the isolates were highly susceptible to
caspofungin (100% of isolates were inhibited at £1 mg/L).
Conclusions: Our results represent further evidence for the excellent antifungal potency of caspofungin,
particularly against C. glabrata isolates expressing cross-resistance to azoles.
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Introduction
Candida glabrata infections have markedly increased in the past
decades and, when invasive, are associated with a high mortality
rate, especially in immunocompromised patients such as
intensive-care, post-surgical and neutropenic patients.1 This, in
part, has been attributed to the reduced susceptibility of this
pathogen to antifungal agents, especially the azoles.2 Recent
studies revealed that the MICs of extended-spectrum triazoles
(fluconazole, itraconazole and voriconazole) for C. glabrata
were higher than those seen for most Candida albicans isol-
ates.3–6 Fluconazole-resistant isolates have been found not only
in AIDS patients with oropharyngeal candidiasis, but also in
fungaemic patients and among vaginal isolates as a consequence
of widespread and often indiscriminate use of the drug.7 C. glab-
rata is able to rapidly develop azole resistance, which is probably
related to the haploid state of the microorganism.2 In this context,
studying the resistance mechanisms of this pathogenic yeast may
provide answers in developing new antifungal agents.6,8
Caspofungin is an echinocandin with potent fungicidal activity
against many Candida species3,9 and could be particularly useful
to treat C. glabrata infections, which often develop resistance to
azoles. To further demonstrate the in vitro efficacy of this
promising new antifungal agent in C. glabrata, we report here
caspofungin susceptibility of a large collection of clinical isolates
which were cross-resistant to multiple azoles. Molecular studies
showed that azole resistance in these isolates is associated with
the up-regulation of the ABC transporter genes CgCDR1 and
CgCDR2.
Materials and methods
Yeast isolates and antifungal susceptibility testing
A total of 50 clinical isolates of azole-resistant C. glabrata were
tested: 30 isolates were recovered from blood (4 isolates), respiratory
tract (10), vagina (3), mouth (1), urine (10), skin (1) and drainage
fluid (1) of patients hospitalized between January 2004 and June
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2005, and 20 other isolates, cultured from various patient specimens
(6 blood, 5 urine, 3 vagina, 2 respiratory tract, 2 mouth, 1 skin and 1
drainage fluid) before 2004, had been explored for molecular mech-
anisms of antifungal resistance in a previous study.6 Each isolate
represented an individual infectious episode. The isolates showed
high MICs of multiple azoles, as determined by the broth microdi-
lution method (Table 1). A panel of 30 fluconazole-susceptible or
fluconazole-susceptible dose-dependent (S-DD) isolates was also
included. All isolates were identified to the species level by standard
methods10 and stored as 20% glycerol stocks until use. Prior to
testing, each isolate was subcultured onto Sabouraud dextrose
agar. C. glabrata ATCC 36909 reference strain and two well-char-
acterized C. glabrata isolates, DSY562 (a susceptible isolate) and
DSY565 (a resistant isolate),11 were included as controls. Antifungal
susceptibility testing was performed by the broth microdilution
method in RPMI with 2% glucose according to the M27-A2 docu-
ment of the Clinical and Laboratory Standards Institute (CLSI, for-
merly the NCCLS).12 The inoculum suspensions were adjusted
spectrophotometrically at 530 nm to match the concentration of
1.5 – 1.0 · 103 cells/mL. Stock solutions of caspofungin (Merck
& Co., Whitehouse Station, PA, USA), fluconazole (Pfizer, Inc.,
New York, NJ, USA), itraconazole (Janssen, Beerse, Belgium), keto-
conazole (Sigma Aldrich, Milan, Italy) and voriconazole (Pfizer)
were prepared in water (caspofungin and fluconazole) or dimethyl
sulphoxide (itraconazole, ketoconazole and voriconazole). The final
concentrations of the antifungal agents were 0.008–8 mg/L
for caspofungin, itraconazole, ketoconazole and voriconazole and
0.125–128 mg/L for fluconazole. The trays were incubated at
35C, and MIC end points were read at 48 h. All tests were carried
out in duplicate. For caspofungin, the MIC end point was defined as
the lowest concentration determining complete inhibition of growth.
This end point was chosen based on the fungicidal activity of caspo-
fungin as already described.9 For azoles, the MIC end point was
defined as the lowest concentration that produced a prominent
decrease in turbidity (80% inhibition) compared with that of the
growth control. The interpretive criteria used for fluconazole, itra-
conazole and voriconazole were those published by the CLSI.12,13
Interpretive breakpoints have not yet been established for either
ketoconazole or voriconazole, but we used susceptibility breakpoints
of £0.125 and £1 mg/L, respectively.6 The CLSI quality control
strains Candida krusei ATCC 6258 and Candida parapsilosis
ATCC 22019 were tested and MICs were within the expected range.
Rhodamine 6G accumulation assay
The rhodamine 6G accumulation assay was performed as described
previously.11,14 Following growth overnight in YEPD (1% yeast
extract, 2% peptone, 2% glucose) liquid medium at 30C, yeast
cells were diluted 100-fold in 5 mL of the same medium. The culture
was grown to reach a cell density of 107 cells/mL, then placed at
4C and divided into 1 mL aliquots. Labelling of the cells (107) with
10 mM rhodamine 6G (Societa` Italiana Chimici, Rome, Italy) was
performed under constant shaking for 30 min at 30C, then stopped
by placing reaction tubes on ice. The labelled cells were diluted 40-
fold in ice-cold 0.1 M phosphate-buffered saline (PBS) at pH 7.0 and
then subjected to flow cytometry using a Coulter EPICS XL instru-
ment (Beckman Coulter, Brea, CA, USA). Experiments were
repeated two times.
Expression levels of ABC transporter genes
Quantitative expression of the CgCDR1 and CgCDR2 genes was
performed by real-time RT–PCR analysis with an i-Cycler iQ system
(Bio-Rad Laboratories, Hercules, CA, USA), following a previously
described protocol.6 Relative quantification of the target gene was
carried out by using a primer pair and a Taqman probe in combina-
tion with primers and a probe specific for the URA3 reference gene.
Each reaction was performed in triplicate. For each isolate, fold
increases in gene expression were calculated from the mean
normalized expression relative to the mean normalized expression
of the DSY562 isolate, used as a susceptible control.15 Genes with a
DCT value, calculated as CT [test gene]–CT [URA3], that fell over
the 3-SD range measured in the azole-susceptible isolates were
considered overexpressed, as reported previously.16
Results and discussion
Table 1 summarizes the in vitro susceptibility of 80 C. glabrata
clinical isolates to caspofungin, itraconazole, ketoconazole and
voriconazole stratified by fluconazole susceptibility category.
With respect to fluconazole MIC, the isolates fell into the fol-
lowing groups: susceptible (15 isolates), S-DD (15 isolates) and
resistant (50 isolates). All fluconazole-resistant isolates were also
cross-resistant to the other azoles tested (Table 1), and this
phenotype was found to be associated with the overexpression
of drug efflux pump-encoding CgCDR genes. The expression of
CgCDR1 and CgCDR2 was strongly increased in the majority of
the 50 azole-resistant isolates compared with that of the suscept-
ible control isolate DSY562, but not in the 15 azole-susceptible
isolates studied (Figure 1). Of the resistant isolates 46 exhibited
12.4- to 483.0-fold up-regulation of the ABC transporter gene
CgCDR1. Notably, 27 of these 46 also exhibited 3.9- to 70.6-fold
up-regulation of CgCDR2, with the remaining 4 isolates showing
26.1- to 61.2-fold up-regulation of this second ABC transporter
gene. The 15 fluconazole-S-DD isolates up-regulated CgCDR1 or
CgCDR2 (Figure 1), but the levels of up-regulation were signi-
ficantly less than those by the resistant isolates studied (109.9- to
5.5-fold for CgCDR1 and 17.4- to 2.6-fold for CgCDR2).
Furthermore, the increased expression of efflux pumps in the
fluconazole-resistant and fluconazole-S-DD isolates was also
accompanied by decreased accumulation of rhodamine 6G, as
shown by their mean fluorescence values, which differed from
Table 1. In vitro activity of caspofungin and azole antifungal agents
against 80 clinical isolates of C. glabrata stratified by fluconazole
susceptibility
Fluconazole
susceptibility
categorya
No.
tested
Antifungal
agent
MIC range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
S 15 caspofungin 0.03–0.125 0.06 0.125
itraconazole 0.125–0.5 0.25 0.5
ketoconazole 0.06–0.25 0.125 0.25
voriconazole 0.06–0.25 0.125 0.125
S-DD 15 caspofungin 0.03–0.25 0.125 0.25
itraconazole 0.125–2 0.5 1
ketoconazole 0.06–0.5 0.125 0.5
voriconazole 0.125–1 0.25 0.5
R 50 caspofungin 0.06–1 0.25 1
itraconazole 2–>8 8 >8
ketoconazole 1–8 4 4
voriconazole 2–8 4 8
aS, MIC £ 8 mg/L; S-DD, MIC = 16–32 mg/L; R, MIC ‡ 64 mg/L.
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those of the susceptible isolates by 96.1- and 37.0-fold,
respectively (Figure 1). In contrast, caspofungin was very active
in vitro against all the fluconazole-resistant and fluconazole-S-
DD isolates and, as expected, against the fluconazole-susceptible
isolates. MIC90 (MIC at which 90% of the isolates were
inhibited) of fluconazole-resistant isolates was 1 mg/L. MIC90s
of fluconazole-S-DD isolates and fluconazole-susceptible isolates
were 0.25 and 0.125 mg/L, respectively. For all the isolates, the
MIC of caspofungin was £1 mg/L. Low MICs (0.06 mg/L) of
caspofungin were also obtained for the C. glabrata reference
strain, ATCC 36909, and two well-characterized C. glabrata
isolates, DSY562 and DSY565.
Cross-resistance within a class of antimicrobial agents is an
important issue, especially if therapeutic options are limited by a
poor number of available compounds as for the antifungal agents.
Although the new systemic antifungal triazoles (ravuconazole and
voriconazole) are more active in vitro than fluconazole and itra-
conazole against Candida spp.,17 cross-resistance between fluc-
onazole and ravuconazole has been observed, so that fluconazole
was recently proposed as a surrogate marker to predict the
susceptibility of Candida spp. to ravuconazole.18 The cross-
resistance involving ravuconazole,18 like that involving
voriconazole,4,6 applies most directly to fluconazole-resistant
C. glabrata. As stated by Sobel,7 C. glabrata can be considered
the Achilles heel of all available azoles, thus C. glabrata
infections treated with these drugs are difficult to eradicate.
Our results showed that caspofungin had excellent activity
against fluconazole (multiazole)-resistant isolates, as well as
against isolates susceptible and dose-dependent susceptible to
fluconazole. This is not surprising considering that the echino-
candin caspofungin belongs to a class of antifungal agents that act
by inhibiting the cell wall glucan synthesis. Interestingly,
fluconazole-resistant isolates showed a higher MIC90 value
compared with fluconazole-S-DD or fluconazole-susceptible
isolates. This difference indicates that azole resistance can
contribute to an increase in caspofungin MIC. The basis for
such a difference is still unknown.
In conclusion, the present study confirms the efficacy of
caspofungin against clinical isolates of C. glabrata, but, for
the first time, the potent activity of this drug was assessed
with a large number of C. glabrata isolates whose cross-azole
resistance was well documented by molecular methods. Further-
more, these findings support the use of caspofungin to treat those
C. glabrata infections for which amphotericin B represents the
sole therapeutic choice.
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Figure 1. Expression of ABC transporters CgCDR1 (a) and CgCDR2 (b) and
rhodamine 6G accumulation (c) in C. glabrata clinical isolates. With respect to
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